Mesalamine was approved for medical use in the United States in 1987. Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.

Market Analysis and Insights: Global Mesalamine API Market
The global Mesalamine API market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Mesalamine API Scope and Market Size
The global Mesalamine API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mesalamine API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Purity ≥ 97 %
Purity ≥ 98 %
Purity ≥ 99 %

Segment by Application
Mesalamine Tablets
Mesalamine Capsules
Others

The Mesalamine API market is analysed and market size information is provided by regions (countries). Segment by Application, the Mesalamine API market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Syntese A/S
Divis Laboratories
Cambrex Corporation
Ipca Laboratories
PharmaZell
Lasa Loboratory
Erregierre SpA
Corden Pharma Bergamo
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical